Antisense Therapy Market Size was valued at USD 3.1 Billion in 2022. The Antisense Therapy market industry is projected to grow from USD 3.7 Billion in 2023 to USD 15.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 19.60% during the forecast period (2024 - 2032). Increasing Demand for RNAi and Antisense Therapeutics and Growing Cancer Burden to Drive Market Growth are the key market drivers boosting the expansion of the market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
January 2025: Alloy Therapeutics disclosed the conclusion of a target-specific collaboration and license contract with Sanofi regarding the AntiClastic™ Antisense Platform. The objectives of this partnership are to develop therapeutics that employ antisense technology and focus on intracellular disease mechanisms.
November 2024: Ionis Pharmaceuticals embarked on a pivotal clinical investigation for ION373, a brand new antisense medication for Alexander disease, an uncommon and typically lethal neurological condition. This is a major development for previously neglected areas of research in neurogenetic disorders.
August 2024: Alnylam Pharmaceuticals has presented supporting documentation for douthe dosed vutrisiran, an RNAi therapeutic for ATTR amyloidosis with cardiomyopathy. The drug was shown to decrease the risk of death by 31 percent after 30 months, followed by 36 percent after 42 months. However, the results were disappointing relative to what the investors had expected, causing the company's stock to drop 8.5 percent.
Market CAGR for antisense therapy is being driven by the growing cancer burden. The selective and sequence-specific suppression of the expression of genes by single-stranded DNA oligonucleotides is known as antisense treatment. It controls how cells divide and operate as well as how they react to pressures and stimuli from the outside and inside the cell. In addition, Huntington's, Alzheimer's, and amyotrophic lateral sclerosis are treated with it. Conversely, double-stranded RNA (dsRNA) is the stimulus for RNA interference (RNAi) therapy, which results in sequence-specific breakdown of single-stranded targeted RNAs in response to dsRNA.
Additionally, one of the main factors propelling the market is the increasing need for RNAi and antisense therapies to treat rare neurological illnesses like familial ATTR amyloidosis. In addition, there is a increase in the need for disease management that controls gene expression through defective genes. This is fueling the market's expansion together with the expanding healthcare sector. Furthermore, major industry participants are heavily funding R&D endeavors in order to create compounds utilizing antisense technology. Additionally, they are partnering with contract research organizations (CROs) that focus on drug delivery, which is bolstering the market's expansion. Furthermore, the increasing need for antisense RNA to delay the development of disease and slow its progression is favorably impacting the.
Antisense oligonucleotides are currently advised for cancer therapy in part due to the increasing need for antisense and RNA interference (RNAi) medicines to address rare neurological disorders including hereditary ATTR amyloidosis. Despite challenges such as a poorly understood mechanism of action and customized administration for clinical settings, antisense oligonucleotides are making headway as anticancer medications. Clinical trial performance of these molecules is expected to be improved by continuing research into several chemical modifications that confer greater capabilities upon this nucleotides. The revolutionary advancement of CRISPR-CASs genome editing technology has had an impact on the field of biomedical science. The potential applications of antisense RNA treatments in immunotherapy, personalized medicine, genetics, and other fields mean that they will surely continue to be developed for many years to come.
For instance, the World Health Organization (WHO) estimates 25% of all deaths are attributable to cancer, with lung cancer accounting for 30% of these cases. Around 25% of new cases in men and around 25% in women are prostate and breast cancer, respectively, the most frequent cancers. Although it is rare (approximately 150 cases per million in the United States), leukemia is the most prevalent type of cancer that affects children and adolescents. About 230 cases per million occur in the United States during the first year of life, with neuroblastoma being the most prevalent, demand for Antisense Therapy supplements will increase due to Growing Cancer Burden. Thus, result in driving the Antisense Therapy market revenue.
The Antisense Therapy market segmentation, based on application includes Genetic Disease, Cancer, Infectious Disease, Neurodegenerative Disorders, Cardiometabolic & Renal Disorders, Ocular Disorders, Respiratory Disorders, Skin Disorders, Others. The genetic disease segment dominated the market. Because of The use of oligonucleotide products is anticipated to be impacted by the growing need to treat and manage conditions such spinal muscular atrophy and Duchenne muscular dystrophy (DMD). The number of research studies on oligonucleotide therapeutics is increasing, indicating a rapid expansion of this field of study.
The Antisense Therapy market segmentation, based on Route of Administration, includes Intravenous Injections, Intrathecal Injections. The intrathecal injections segment generated the most income. Because of It is a method of administering medication that involves injecting it into the spinal canal or subarachnoid space to reach the CSF. This method is applied in pain management, spinal anesthetic, chemotherapy, and the introduction of medications to fight particular infections, especially following neurosurgery procedures.
Figure1:Antisense Therapy Market, by Route of Administration,2022&2032(USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Antisense Therapy market area will dominate this market, owing to the increased need for efficient therapies as knowledge and diagnosis of certain illnesses rise. Research institutes and pharmaceutical corporations in the United States are making significant investments in the creation of antisense medicineswill boost market growth in this region.
Further, the major countries studied in the market report are The US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.
Figure2:ANTISENSE THERAPY MARKET SHARE BY REGION 2022 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Europe Antisense Therapy market has the second-largest portion of the market due to the low cost rising accelerated through collaboration between biotech, pharmaceutical, and academic organizations. Through partnerships, companies can gain access to resources, knowledge. Further, the German Antisense Therapy market had the biggest market share, and the UK Antisense Therapy market was the fastest growing market in the European region
The Asia-Pacific Antisense Therapy Market is anticipated to expand between 2023 and 2032 at the quickest CAGR. This is due to the development and uptake of cutting-edge treatments like antisense technology is made possible by increased public and private sector. Moreover, China’s Antisense Therapy market had the biggest market share, and the Indian Antisense Therapy market was the fastest growing market in the Asia-Pacific region.
Antisense Therapy Key Market Players& Competitive Insights
Leading market players are putting a lot of money on R&D to expand their product lines, which will help the market for weight reduction products grow. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, Antisense Therapy industry must provide reasonably priced goods.
Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the Antisense Therapy industry to help customers and expand the market segment. In recent years, the Antisense Therapy industry has provided some of the biggest benefits to medicine. Major players in the Antisense Therapy market, including GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc., Arbutus Biopharma, Benitec Biopharma Inc., Silence Therapeutics., and others, are attempting to increase market demand by investing in research and development operations.
Olix Pharmaceuticals works on the creation, production, distribution, and study of pharmaceutical products. Their areas of specialization could include cancer, neurology, cardiology, immunology, and infectious illnesses, among other therapeutic domains.This entails either creating whole new medications or refining those that already exist. It covers things like preclinical research, clinical trials, lead optimization, and target identification. In March 2023, In a Phase 1 clinical trial of an experimental RNAi therapy intended to treat age-related macular degeneration (AMD), OliX Pharmaceuticals, Inc. dosed the first patient.
The biopharmaceutical business Alnylam Pharmaceuticals, Inc. is well-known for its contributions to RNA interference (RNAi) treatments. Alnylam is a leader in the development of RNAi treatments, a state-of-the-art approach that "turns off" or silences particular genes linked to disease using small interfering RNA (siRNA). By focusing on the underlying genetic causes of a variety of diseases, this technique offers the potential to treat them all. In July 2023 Alnylam Pharmaceuticals, Inc. and Roche collaborated to create and commercialize zilebesiran, an RNA interference (RNAi) treatment under research for the treatment of hypertension.
Key Companies in the Antisense Therapy market include
Olix Pharmaceuticals, Inc.
Sanofi
Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma
Benitec Biopharma Inc.
Silence Therapeutics
Ionis Pharmaceuticals, Inc
Bio-Path Holdings Inc.
Antisense Therapeutics Limited.
Antisense Therapy Industry Developments
September 2023: Ionis Pharmaceuticals revealed positive results from Phases 3 clinical trials for the antisense oligonucleotide drug , tofersen, which target superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The study reported considerable decreases in the SOD1 protein levels and mitigation of the disease advancement.
June 2023: Biogen Inc. received FDA endorsement for -Qalsody (tofersen) an antisense therapy for SOD1-ALS. It is the first medication to ever be approved because it addresses the genetic component of ALS and gives hope to patients suffering from this uncommon ailment.
November 2022: Wave life Sciences unveiled favorable information from its Phase 1b2a trial of WVE-004, which is an investigational antisense oligonucleotide for patients with C9orf72 associated amyotrophic lateral sclerosis or frontotemporal dementia. This therapy seemed to reduce significantly the poly(GP ) dipeptide repeat proteins which shows engagement with the target
April 2022: ProQR Therapeutics made an announcement for a partnership with Eli Lilly and Company to formulate new genetic medicines based on ProQR’s Axiomer proprietary RNA editing platform. The focus of this collaboration is to tackle diseases that cannot be easily addressed by current antisense therapies.
Genetic Disease
Cancer
Infectious Disease
Neurodegenerative Disorders
Cardiometabolic & Renal Disorders
Ocular Disorders
Respiratory Disorders
Skin Disorders
Others
Intravenous Injections
Intrathecal Injections
| Report Attribute/Metric | Details |
| Market Size2022 | USD 3.1 Billion |
| Market Size 2023 | USD 3.7 Billion |
| Market Size2032 | USD 15.5 Billion |
| Compound Annual Growth Rate (CAGR) | 19.60% (2023-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Application, Route of Administration, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, German, France, UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil |
| Key Companies Profiled | Â GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc., Arbutus Biopharma, Benitec Biopharma Inc., Silence Therapeutics |
| Key Market Opportunities | Increasing Number of Product Launches for Novel Antisense Oligonucleotides |
| Key Market Dynamics | Growing Cancer Burden to Drive Market Growth |
Frequently Asked Questions (FAQ) :
The Antisense Therapy market size was valued at USD 3.1 Billion in 2022.
The market is projected to grow at a CAGR of 19.60% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc., Arbutus Biopharma, Benitec Biopharma Inc., Silence Therapeutics
The genetic disease dominated the market in 2022.
The Intrathecal Injections had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
